Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play

Natalie Grover

Reporter

Two months after one of the largest single private funding rounds for a biotech company in European history, German cancer drug developer BioNTech is gunning for a $100 million US IPO.

Helmut Jeggle

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play

Natalie Grover

Reporter

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Sage focuses on successful launch of postpartum depression drug

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access

Fresh off the heels of mega fi­nanc­ing round, Ger­many's BioN­Tech makes $100M US IPO play

Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Fresh off the heels of mega financing round, Germany's BioNTech makes $100M US IPO play